COVID-19NEU-COVIDNCT05413824
Neutrophil Side Fluorescent Light (NEU-SFL) in COVID-19 Patients
An observational study of COVID-19, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
Trial summary
Recently, a study showed that markers of neutrophil extracellular traps formation, a mechanism corresponding to neutrophil activation, were increased in patients who died of COVID 19 compared with survivors. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19
- How many people
- 2,233 participants
- Where
- 1 siteFrance
- Study dates
- 2 Jun 2022to 31 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All adult patients hospitalized for COVID-19 at Nimes Hospital in 2021.
Who may be able to join
- Hospitalization for COVID 19 in 2021
Who cannot join
- Patients who refused the use of their data
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Neutrophil Side Fluorescent Light (NEU-SFL) in COVID-19 Patients Hospitalized in 2021
Recently, a study showed that markers of neutrophil extracellular traps formation, a mechanism corresponding to neutrophil activation, were increased in patients who died of COVID 19 compared with survivors.
The investigators propose to analyze the NEU-SFL parameter, obtained automatically on the Sysmex™ blood count machine (Sysmex Corporation, Kobe, Japan) and which is considered as a reflect of neutrophil extracellular traps formation, in these two groups of patients. The aim was to evaluate whether this parameter could be used to predict the risk of death related to COVID 19.
- Conditions
- COVID-19
- Keywords
- COVID-19, neutrophil extracellular traps (NETs)
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| COVID-19 survivors | Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who survived. | |
| COVID-19 Deceased | Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who died. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare the rate of NEU-SFL in patients hospitalized at Nimes hospital for COVID-19 in 2021, according they survived or not.
Data collection
Measured: 3 months
Secondary outcomes (2)
Compare the rate of NEU-SFL in patients hospitalized at Nimes hospital for COVID-19 in 2021 who survived, between entry and discharge from Nimes hospital
Data collection
Measured: 3 months
Compare the rate of NEU-SFL in patients hospitalized at Nimes hospital for COVID-19 in 2021 who died, between entry and discharge from Nimes hospital
Data collection
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2022
- Study start2 Jun 2022
- Primary completion31 Dec 2022
- Study completion31 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 2,233 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Anissa MEGZARI, Study chair, CHU Nimes
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05413824
- Sponsor's protocol ID
- Local/2022/SB-01
- Acronym
- NEU-COVID
- Status last verified
- Feb 2023
- First submitted
- 9 Jun 2022
- Last updated
- 4 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Fortier M, Chea M, Ain C, Loyens M, Boudemaghe T, Gris JC, Bouvier S. Direct blood fluorescence signal intensity of neutrophils (NEU-SFL): A predictive marker of death in hospitalized COVID-19 patients? Front Med (Lausanne). 2022 Dec 21;9:1062112. doi: 10.3389/fmed.2022.1062112. eCollection 2022.
PubMed 36619613
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neutrophil Side Fluorescent Light (NEU-SFL) in COVID-19 Patients Hospitalized in 2021
- ClinicalTrials.gov ID
- NCT05413824
- Acronym / sponsor ID
- NEU-COVID / Local/2022/SB-01
- Conditions
- COVID-19
- Keywords
- COVID-19, neutrophil extracellular traps (NETs)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,233 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 2 Jun 2022 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 10 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recently, a study showed that markers of neutrophil extracellular traps formation, a mechanism corresponding to neutrophil activation, were increased in patients who died of COVID 19 compared with survivors.
The investigators propose to analyze the NEU-SFL parameter, obtained automatically on the Sysmex™ blood count machine (Sysmex Corporation, Kobe, Japan) and which is considered as a reflect of neutrophil extracellular traps formation, in these two groups of patients. The aim was to evaluate whether this parameter could be used to predict the risk of death related to COVID 19.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| COVID-19 survivors | – | –Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who survived. |
| COVID-19 Deceased | – | –Patients hospitalized at Nimes university hospital in 2021 for COVID-19 who died. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All adult patients hospitalized for COVID-19 at Nimes Hospital in 2021.
Key inclusion criteria (1 listed)
- Hospitalization for COVID 19 in 2021
Key exclusion criteria (1 listed)
- Patients who refused the use of their data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To compare the rate of NEU-SFL in patients hospitalized at Nimes hospital for COVID-19 in 2021, according they survived or not.
Time frame: 3 months
Data collection
2 secondary outcomes
Compare the rate of NEU-SFL in patients hospitalized at Nimes hospital for COVID-19 in 2021 who survived, between entry and discharge from Nimes hospital
Time frame: 3 months
Compare the rate of NEU-SFL in patients hospitalized at Nimes hospital for COVID-19 in 2021 who died, between entry and discharge from Nimes hospital
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2025.
- Results publication: PubMed 36619613Fortier M, Chea M, Ain C, Loyens M, Boudemaghe T, Gris JC, Bouvier S. Direct blood fluorescence signal intensity of neutrophils (NEU-SFL): A predictive marker of death in hospitalized COVID-19 patients? Front Med (Lausanne). 2022 Dec 21;9:1062112. doi: 10.3389/fmed.2022.1062112. eCollection 2022.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anissa MEGZARI study chair
CHU Nimes
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare the rate of NEU-SFL in patients hospitalized at Nimes hospital for COVID-19 in 2021, according they survived or not. (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05413824, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.